Frailty may not limit semaglutide benefits - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Frailty may not limit semaglutide benefits

Patients with greater frailty showed larger improvements in health-related quality of life, while cardiovascular treatment effects did not differ significantly across frailty categories.

  • By

  • Andrea Surnit

  • October 16, 2026

  • 5 min

Share

Original Source(s)

Frailty may not limit semaglutide benefits

  • by Andrea Surnit

  • October 16, 2026

Related Content

Emergency diagnosis may flag poor outcomes beyond cancer

Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality.

Mortality score may refine heart allocation

A laboratory- and device-based model outperformed the current 6-status system in predicting short-term mortality among heart transplant candidates.

Tricuspid regurgitation thresholds reassessed

The proposed framework classified 30% of patients as high or extreme risk, compared with 12% classified as having severe or greater tricuspid regurgitation under established grading schemes.